A Study to Evaluate Efficacy and Safety of HM11260C in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 118 participants.

Also called NCT07379333

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 118 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07379333
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07379333. Randomized; double masking; primary purpose treatment. Start 2026-04-13 (actual); primary completion 2027-11 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate Efficacy and Safety of HM11260C in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin
Intervention (Drug)
HM11260C
Intervention (Drug)
Placebo
Lead sponsor
Hanmi Pharmaceutical Company Limited (class: industry)

Record details

Record id
cardio:ct-nct07379333
Content hash
9a90964b8a20fe0e0223a1ae3c72fe16bd59ed1df9b80084ca1fa0f8f9bb0cf4